Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senicapoc in Mild or Prodromal Alzheimer's Disease
NCT04804241Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Mar 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of senicapoc in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by University of California, Davis. Started Mar 2022; status: recruiting.
02
Drugs
senicapoc
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04804241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804241.